In a conference at the 16th National Meeting of the Integrated Health Program for Diabetic Patients, the scientist said that the therapy has gained great recognition within the U.S. medical community involved in those treatments.
Cuban doctors who created the product as well as the health staff using it on the island hope that, in the near future, Heberprot-p will be used in the United States; a country with an average of 220 daily amputations due to diabetic foot ulcers.
Berlanga commented that prospects are huge for the potential use of Heberprot-p in the neighboring country and that Cuba may serve as an example to the world in terms of clinical and medical achievements that go far beyond commercial goals.
He referred to his participation at the Global Diabetic Foot Conference held in the American city of Hollywood in late March, where he was given the honor of giving the opening lecture.
The scientist said that he had the pleasure of witnessing the ever increasing acceptance and prestige that Heberprot-p continues to gain among scientists, general practitioners, surgeons, and other specialists. Equally gratifying is the fact that prominent professors have read Cuban publications on the topic, he added.
The highly specialized U.S. medical community is very familiar with this Cuban experience, the primary healthcare strategy, and the active control of patients with risks of developing diabetic foot ulcers so as to provide them with early treatment, Berlanga noted.
There is a large number of U.S. professionals and diabetic foot specialists willing to use the Cuban medicine, which they recognize as an effective and feasible way to reduce the 70,000 to 80,000 amputations annually performed. / By PL.